STOP-CA Clinical Trial Finds Statins Lower Rate of Heart Decline in Lymphoma Patients, Late-Breaking ACC23 Clinical Trial Reports
In conducting the “Statins to Prevent the Cardiotoxicity from Anthracyclines: The STOP-CA Trial,” researchers found that among people receiving chemotherapy regimens containing anthracyclines for lymphoma, those who took the cholesterol-lowering drug atorvastatin for one year were significantly less likely to show evidence of heart dysfunction than those who took a placebo. FIndings were reported during the first late-breaking clinical trial session during the March 4-6 American College of Cardiology’s Annual Scientific Session Together with the World Congress of Cardiology, ACC.23/WCC.
Source: dicardiology.com